Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: Subgroup analysis of Korean women

BMC Pregnancy and Childbirth

Volumn 18, Issue 1, 2018, Pages

  Shim, Jae Yoon ^a   Kim, Moon Young ^b   Kim, Young Ju ^c   Lee, Young ^d   Lee, Jeong Jae ^e   Jun, Jong Kwan ^f   Shin, Jong Chul ^d   Cho, Yong Kyoon ^g   Lee, Keun Young ^h   Kim, Ahm ^a   Song, Tae Bok ⁱ  

^a University of Ulsan College of Medicine   (South Korea)

^b Dankook University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Soonchunhyang University College of Medicine   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Hallym University College of Medicine   (South Korea)

ⁱ Chonnam National University Medical School   (South Korea)

Author keywords

Anemia; Clinical trial; Ferric carboxymaltose; Intravenous iron; Iron deficiency; Korea; Pregnancy

Indexed keywords

FERRIC CARBOXYMALTOSE; FERROUS SULFATE; HEMOGLOBIN; FERRIC ION; FERROUS ION; MALTOSE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MATERNAL AGE; MENTAL FUNCTION; NAUSEA; NUTRITIONAL PARAMETERS; PHYSICAL CAPACITY; POST HOC ANALYSIS; PREGNANCY; PREGNANT WOMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH KOREAN; ANALOGS AND DERIVATIVES; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PREGNANCY COMPLICATION; SOUTH KOREA; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HEMOGLOBINS; HUMANS; MALTOSE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 85052519300     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/s12884-018-1817-y     Document Type: Article

References (24)

1. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615-24.
2. Pasricha SR, Drakesmith H, Black J, Hipgrave D, Biggs BA. Control of iron deficiency anemia in low- and middle-income countries. Blood. 2013;121:2607-17.
3. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. Lancet Glob Health. 2013;1:e16-25.
4. Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008;87:949-59.
5. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72(1 Suppl):257S-64S.
6. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832-43.
7. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010;282:577-80.
8. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588-600.
9. Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J, investigators F-A. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017;45:443-53.
10. Lee JO, Lee JH, Ahn S, Kim JW, Chang H, Kim YJ, et al. Prevalence and risk factors for iron deficiency anemia in the korean population: results of the fifth Korea National Health and Nutrition Examination Survey. J Korean Med Sci. 2014;29:224-9.
11. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267-78.
12. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-53. e1-2
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
14. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-607.
15. Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth. 2014;14:115.
16. Dasararaju R, Marques MB. Adverse effects of transfusion. Cancer Control. 2015;22:16-25.
17. Kim S, Park Q, Park JR, Kim HO. International comparison of blood product prices. Korean J Blood Transfus. 2009;20:75-83.
18. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48.
19. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40:469-74.
20. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One. 2014;9:e94217.
21. Calvet X, Ruiz MA, Dosal A, Moreno L, Lopez M, Figuerola A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One. 2012;7:e45604.
22. Fragoulakis V, Kourlaba G, Goumenos D, Konstantoulakis M, Maniadakis N. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Clinicoecon Outcomes Res. 2012;4:127-34.
23. Wilson PD, Hutchings A, Jeans A, Macdougall IC. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J Med Econ. 2013;16:108-14.
24. Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject(R)) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost Eff Resour Alloc. 2014;12:19.